AB801

DRUG2 trials

Sponsors

Arcus Biosciences, Inc.

Conditions

Advanced CancerCancer

Phase 1

A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers

CompletedNCT06004921

Arcus Biosciences, Inc.Cancer

Start: 2023-10-16End: 2024-02-23Updated: 2024-08-28

A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Active, not recruitingNCT06120075

Arcus Biosciences, Inc.Advanced Cancer

Start: 2024-01-19End: 2026-11-01Target: 91Updated: 2026-08-13

Related Papers

Abstract A015: AB801, a potent and selective clinical-stage AXL inhibitor, enhances the anti-tumor efficacy and duration of response of KRAS inhibitors

Cancer Research2026-03-05

Abstract A100: AXL Inhibitor AB801 Increases the Anti-Tumor Efficacy of KRAS Inhibition

Molecular Cancer Therapeutics2025-10-22

Abstract A011: Discovery and characterization of the first highly potent and selective AXL receptor tyrosine kinase inhibitor AB801

Molecular Cancer Therapeutics2024-12-09